Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

By Huilin Shao, Jaehoon Chung, L. Balaj, A. Charest, D. Bigner, B. Carter, F. Hochberg, X. Breakefield, Ralph Weissleder, Hakho Lee. Nature Medicine, 2012

725 citations recorded by the source corpus.

Glioblastomas shed large quantities of small, membrane-bound microvesicles into the circulation. Although these hold promise as potential biomarkers of therapeutic response, their identification and quantification remain challenging. Here, we describe a highly sensitive and rapid analytical technique for profiling circulating microvesicles directly from blood samples of patients with glioblastoma. Microvesicles, introduced onto a dedicated microfluidic chip, are labeled with target-specific magnetic nanoparticles and detected by a miniaturized nuclear magnetic resonance system. Compared with current methods, this integrated system has a much higher detection sensitivity and can differentiate glioblastoma multiforme (GBM) microvesicles from nontumor host cell–derived microvesicles. We also show that circulating GBM microvesicles can be used to analyze primary tumor mutations and as a predictive metric of treatment-induced changes. This platform could provide both an early indicator of drug efficacy and a potential molecular stratifier for human clinical trials.

Subfields: Biomedical Engineering, Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/ca64061c3e473a2d165b7d1cd0cc88d1c11ded9c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

Suresh Mathivanan

In Cancer Research

In Molecular Biology

Citations in the corpus

Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies (2013, neutral): “[121] report the fabrication of a microfluidic chip that quantifies the presence Nucleus Apoptosis Apoptotic bodies”
Standardization of sample collection, isolation and analysis methods in extracellular vesicle research (2013, neutral): “receptor variant EGFRvIII in gliomas (76).”
Plasma Proteome Database as a resource for proteomics research: 2014 update (2013, background): “EVs are shown to be present in plasma from healthy and certain cancer patients including glioblastoma and colon cancer (45,46).”